PDCD1 and Hodgkins lymphoma: Our previous work showed that a combination of decitabine and PD-1-ab enhanced the antitumor efficacy of PD-1 inhibitors and significantly increased the complete remission rate of relapsed and refractory Hodgkin lymphoma from 32 to 71% [1].